Footwear and Injury Prevention Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00832195|
Recruitment Status : Completed
First Posted : January 30, 2009
Last Update Posted : February 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Pronation Control||Device: Motion Controlling Running Shoe Device: Neutral Running Shoe||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||103 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Footwear Prevention Study: Investigating the Effects of Running Shoe Pronation Control on the Risk of Injury|
|Study Start Date :||March 2009|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||December 2009|
Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
Device: Motion Controlling Running Shoe
Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
Active Comparator: 2
Footwear with standard neutral stabilization elements for the foot and ankle during running.
Device: Neutral Running Shoe
Standard running shoe with single density mid-sole foam.
- Injury status, as measured at baseline, 6 weeks, and at the end of the 13-week programme [ Time Frame: 13 weeks ]
- Pain levels, as measured at baseline, 6 weeks, and at the end of the 13-week programme [ Time Frame: 13 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00832195
|Canada, British Columbia|
|Vancouver, British Columbia, Canada|
|Principal Investigator:||Jack Taunton, MD||University of British Columbia|
|Study Director:||Michael Ryan||University of British Columbia|